Ligation of Intersphincteric Fistula Tract Versus Rectal Advancement Flap in the Treatment of Complex Anal Fistula (LIFTRAF-RCT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05263661 |
Recruitment Status : Unknown
Verified February 2022 by Jorge Alejandro Benavides Buleje, Hospital General Universitario Reina Sofía de Murcia.
Recruitment status was: Active, not recruiting
First Posted : March 2, 2022
Last Update Posted : March 2, 2022
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | February 9, 2022 | ||||
First Posted Date ICMJE | March 2, 2022 | ||||
Last Update Posted Date | March 2, 2022 | ||||
Actual Study Start Date ICMJE | January 1, 2013 | ||||
Actual Primary Completion Date | January 1, 2014 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Curation [ Time Frame: 1 year ] Proportion of subjects in each treatment group without fistula recurrence after surgery
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | No Changes Posted | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Ligation of Intersphincteric Fistula Tract Versus Rectal Advancement Flap in the Treatment of Complex Anal Fistula | ||||
Official Title ICMJE | Ligation of Intersphincteric Fistula Tract Versus Rectal Advancement Flap in the Treatment of Complex Anal Fistula: Randomised Clinical Trial | ||||
Brief Summary | Objective: Rectal advancement flap (RAF) is currently considered the gold standard in the treatment of complex anal fistula (CAF). Clinical trials are a priority given the few consistent results available with level 1 evidence. We compare the results of two conservative sphincter techniques: ligation of intersphincteric fistula tract (LIFT) versus RAF. Material and Method: A controlled, randomised clinical trial is conducted in patients operated between 2013 and 2016 in Hospital General Universitario Reina Sofia, Murcia, Spain. The primary objective was to evaluate relapse at 12 months of follow-up, and the secondary objectives were post-op anal continence (Wexner), post-operative complications (haematoma, infection of surgical site, suture dehiscence), duration of surgery and hospitalisation. Post-operative controls 1, 3, 6 and 12 months after surgery. |
||||
Detailed Description | Material and method Design: Phase III, single centre, randomised, open-label, parallel group trial controlled with active comparator, with blind evaluation of results by a non-commercial third party. This study was conducted in 72 patients who had undergone complex anal fistula surgery and met the inclusion criteria. The study was conducted by the Colo proctology Unit of the General and Digestive Surgery Department of Hospital General Universitario Reina Sofia, Murcia, Spain, from February 2013 to June 2016, and approved by the hospital's Independent Ethics Committee (IEC). The study was conducted pursuant to the principles of the Declaration of Helsinki (Seoul, October 2008) and the Good Clinical Practice (GP) standards of the European Economic Community's task force on the efficacy of medicinal substances (1990) and all legislation currently applicable in Spain (Royal Decree 223/2004 of 6 February). Patients with a diagnosis or suspected diagnosis of anal fistula were referred to the Coloproctology Office. At the first visit, demographic data and a clinical history was obtained, followed by a physical examination of the anal region, with rigid anoscopy, ordering an endoanal ultrasound. At a second visit, if the diagnosis of complex anal fistula was confirmed, after providing information about the study, the patient was invited to participate, signed the consent form, and underwent the pre-operative Wexner scale. Patients were allocated a randomisation code for LIFT or RAF on the day of surgery. After surgery, controls were performed on days 7 and 14, by means of a symptoms diary to be completed by each patient, and 1, 3, 6 and 12 months after the surgery, with the Wexner scale calculated in the last control of each patient. Complex anal fistula was defined as a fistula at risk of affecting continence involving more than 30% of the sphincteric apparatus. Infection of surgical site at or near the incision in the 30 days following surgery (28). Haematoma was defined as accumulation of blood in the surgical area, with bluish or violet colouring of the affected area; surgical wound dehiscence was defined as the spontaneous separation of the edges of the wound, in the absence of surgical site infection. The inclusion criteria were patient diagnosed with transsphincteric (medium or high) or suprasphincteric cryptoglandular anal fistula, over 18 years of age, with no abscess at the time of surgery, who agreed to participate and signed the informed consent form, and was capable transsphincteric understanding and following study instructions. The exclusion criteria were minor patient, diagnosed with, or with a suspected diagnosis of, Crohn's disease, malignant anal tumour, tuberculosis or suppurative hidradenitis, a history of radiotherapy of the ano-perineal region, language difficulties that prevent comprehension of the study, or refusal to participate. Each patient's data were collected in the case report form and transferred to a database for their statistical analysis by an analyst unrelated to the study, preserving their anonymity and the treatment group to which they belonged. Study objectives: The primary objective was to show the non-inferiority in therapeutic efficacy of LIFT versus RAF in the surgical treatment of CAF. The primary efficacy endpoint was the proportion of subjects in each treatment group without fistula recurrence 12 months after surgery. The secondary objectives were to show the non inferiority of LIFT versus RAF in therapeutic safety:
Randomisation and surgeries: The subjects were randomised 1:1 to receive LIFT or RAF surgery. Patient randomisation was by randomisation in balanced six-cell blocks; the sequence was custodied by the Teaching Secretary, unrelated to the study. The surgeon requested each patient's randomisation code on the day of surgery. LIFT or RAF. The patients were operated by three surgeons from the Coloproctology Unit, whose learning curve was based on unifying experimental technique (LIFT) criteria in six patients before the start of the study. All the surgeries used epidural anaesthesia.
Peri-operative care and follow-up: All patients were advised to follow a waste-free diet 48 hours before admission, and were given an enema on the night before surgery. All patients received antibiotic prophylaxis with IV amoxicillin/clavulanic acid 2 g half an hour before the start of surgery. Six hours after surgery, liquid diet commenced, progressing to semi-bland for dinner that night, and bland on the first day after surgery. No postoperative antibiotic treatment was indicated. The ward surgeon, unrelated to the study, discharged the patient based on these criteria: afebrile, controlled pain, appropriate oral tolerance and surgical wound correct. All patients received 12 months of follow-up, except for one who left the study after 8 months. After discharge, the patient attended for cleaning of the surgical wound on the following two Fridays, with review of the symptom diary (SD) and evaluation of possible complications by the Coloproctology Unit surgeon. The patient attended a scheduled appointment one month after surgery (1st post-op visit), where he was evaluated and data was collected in the case report form (CRF), the SD was collected and possible complications were evaluated (infection of surgical site, haematoma, wound dehiscence). New appointments were scheduled at 3 (2nd post-op visit) and 6 months (3rd post-op visit), where the patient was evaluated and the respective data were collected. The final visit (4th post-op visit) took place at 12 months, where the post-op Wexner scale was applied. Sample size and statistical analysis: When the study began, publications reported a relapse rate of 0-33% with rectal advancement flap, with an average of 19% (19) and we can assume that the response rate to surgical treatment was approximately 85% for RAF, while the expected response rate for LIFT was 70%, the average of the rates observed in clinical studies published to date, which ranged from 57% to 94% (19). With these data, considering response as the absence of fistula recurrence at 12 months, and in order to obtain a power of 80% to reject the null hypothesis (Ho), that the difference between proportions p1 and p2 was lower than the non-inferiority limit, by a normal asymptotic test for proportions, unilateral for two independent samples, considering that the level of significance was 0.5, assuming that the proportion in the reference group was 85%, the proportion in the experimental group was 70%, the proportion of patients in the reference group relative to the total was 50% and the non-inferiority limit was 10% and the expected withdrawal rate was 5%, 36 patients were required for the reference group and 36 for the experimental group, making a total of 72 patients in the study. The categorical variables were described with mean values and percentages. The continuous variables were described with mean values and standard deviation, or median values and range. The Chi-square or Fisher test was used to compare two qualitative variables, to see whether there was dependence between them. The Bonferroni correction was used for column comparisons. The Student's t-test was used for comparison of the two groups, after checking the normality and homogeneity of variances assumptions with the Kolmogorov-Smirnov and Levene tests, respectively. For the analysis of non-inferiority of the primary and categorical variables, the calculation was through the Farrington-Manning score and Miettinen-Nurminen Score tests, with a level of significance of 0.05 and a non-inferiority limit of 0.10. For the continuous variables, non-inferiority was evaluated by difference of means, with the Mann-Whitney U-test and the Wilcoxon test. All statistical comparisons used a bilateral test with a level of significance of p < 0.05. The primary study analysis was based on the intention-to-treat population. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 3 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: A controlled, randomised clinical trial Masking: Single (Outcomes Assessor)Masking Description: Open Primary Purpose: Treatment
|
||||
Condition ICMJE | Anal Fistula | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Unknown status | ||||
Actual Enrollment ICMJE |
72 | ||||
Original Actual Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | January 1, 2023 | ||||
Actual Primary Completion Date | January 1, 2014 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Not Provided | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT05263661 | ||||
Other Study ID Numbers ICMJE | LIFTRAF-RCT JBB1 ( Other Identifier: HGU Reina Sofia's CEIC ) |
||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Jorge Alejandro Benavides Buleje, Hospital General Universitario Reina Sofía de Murcia | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Hospital General Universitario Reina Sofía de Murcia | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | Hospital General Universitario Reina Sofía de Murcia | ||||
Verification Date | February 2022 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |